{"id":"NCT01220869","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Study of Degarelix in Taiwanese Patients With Prostate Cancer","officialTitle":"An Open-label, Multi-centre Registration Trial, Investigating Efficacy and Safety of Degarelix One-month Dosing Regimen in Taiwanese Patients With Prostate Cancer Requiring Androgen Ablation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2010-10-14","resultsPosted":"2013-12-06","lastUpdate":"2025-04-13"},"enrollment":110,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":["degarelix acetate","Firmagon","FE200486"]}],"arms":[{"label":"Degarelix","type":"EXPERIMENTAL"}],"summary":"A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer.","primaryOutcome":{"measure":"Cumulative Probability of Participants With Testosterone at Castrate Level <= 0.5 ng/mL From Day 28 to Day 168","timeFrame":"From Day 28 to Day 168","effectByArm":[{"arm":"Degarelix","deltaMin":97.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":10,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":110},"commonTop":["Injection site erythema","Injection site pain","Injection site induration","Injection site swelling","Hot flush"]}}